Area of research
Physiology · Psychiatry and Mental health
Research interest
Research focused on Riociguat and Soluble guanylyl cyclase, with related work in Cyclic guanosine monophosphate, Nitric oxide, Guanylate cyclase. Notable publications include 'Soluble Guanylate Cyclase Stimulators and Activators', 'cGMP: a unique 2nd messenger molecule – recent developments in cGMP research and development', and 'Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence'.
The nitric oxide–soluble guanylate cyclase–cGMP pathway in pulmonary hypertension: from PDE5 to soluble guanylate cyclase
Activating soluble guanylyl cyclase attenuates ischemic kidney damage
Soluble guanylyl cyclase stimulators and activators: Promising drugs for the treatment of hypertension?
Treatment effects of soluble guanylate cyclase modulation on diabetic kidney disease at single-cell resolution
Soluble guanylyl cyclase: A novel target for the treatment of vascular cognitive impairment?
Loss of soluble guanylyl cyclase in platelets contributes to atherosclerotic plaque formation and vascular inflammation
Soluble GC stimulators and activators: Past, present and future
Discovery of the Soluble Guanylate Cyclase Activator Runcaciguat (BAY 1101042)
Novel soluble guanylyl cyclase activators increase glomerular cGMP, induce vasodilation and improve blood flow in the murine kidney
Soluble guanylate cyclase stimulators and their potential use: a patent review
Runcaciguat, a novel soluble guanylate cyclase activator, shows renoprotection in hypertensive, diabetic, and metabolic preclinical models of chronic kidney disease
Loss of soluble guanylyl cyclase in platelets contributes to atherosclerotic plaque formation and vascular inflammation
The Novel Soluble Guanylyl Cyclase (sGC) Activator Runcaciguat Induced Renal Vasodilation and Reduced Kidney Damage in a Rat CKD Model
cGMP: a unique 2nd messenger molecule – recent developments in cGMP research and development
Loss of smooth muscle CYB5R3 amplifies angiotensin II–induced hypertension by increasing sGC heme oxidation
Correction to: Soluble Guanylate Cyclase Stimulators and Activators
Protein Kinase G Is Involved in Acute but Not in Long-Term Regulation of Renin Secretion
Soluble Guanylate Cyclase Stimulators and Activators
The Impact of the Nitric Oxide (NO)/Soluble Guanylyl Cyclase (sGC) Signaling Cascade on Kidney Health and Disease: A Preclinical Perspective
From molecules to patients: exploring the therapeutic role of soluble guanylate cyclase stimulators
Nitric oxide–sensitive guanylyl cyclase stimulation improves experimental heart failure with preserved ejection fraction
Discovery and development of sGC stimulators for the treatment of pulmonary hypertension and rare diseases
Inhibition of the <scp>TGF</scp>β signalling pathway by <scp>cGMP</scp> and <scp>cGMP</scp>‐dependent kinase I in renal fibrosis
Nitric Oxide–Independent Soluble Guanylate Cyclase Activation Improves Vascular Function and Cardiac Remodeling in Sickle Cell Disease
Abstracts from the 8th International Conference on cGMP Generators, Effectors and Therapeutic Implications
Anti-fibrotic effects of soluble guanylate cyclase stimulators and activators: A review of the preclinical evidence
Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies
Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFβ signalling
cGMP-Prkg1 signaling and Pde5 inhibition shelter cochlear hair cells and hearing function